• Innovent Biologics' arcotatug tavatecan became the first CLDN18.2-targeted antibody-drug conjugate globally to have a new drug application accepted for regulatory review.
• The Phase 3 gastric cancer study met both primary endpoints, showing statistically significant improvements in overall survival and progression-free survival.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.